Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Interest Expenses (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Interest Expenses for 5 consecutive years, with $63462.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 10.46% year-over-year to $63462.0, compared with a TTM value of $240664.0 through Dec 2025, down 24.41%, and an annual FY2025 reading of $240664.0, down 24.41% over the prior year.
  • Interest Expenses was $63462.0 for Q4 2025 at SAB Biotherapeutics, up from $43292.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $93119.0 in Q2 2024 and bottomed at $43292.0 in Q3 2025.
  • Average Interest Expenses over 5 years is $73519.6, with a median of $73228.0 recorded in 2021.
  • The sharpest move saw Interest Expenses soared 32.33% in 2022, then crashed 44.52% in 2025.
  • Year by year, Interest Expenses stood at $66275.0 in 2021, then surged by 32.33% to $87699.0 in 2022, then fell by 11.2% to $77879.0 in 2023, then dropped by 8.99% to $70876.0 in 2024, then decreased by 10.46% to $63462.0 in 2025.
  • Business Quant data shows Interest Expenses for SABS at $63462.0 in Q4 2025, $43292.0 in Q3 2025, and $64345.0 in Q2 2025.